RiverVest Venture Partners is a venture capital firm that specializes in early-stage investments in the healthcare sector. The firm focuses on identifying and nurturing innovative companies that address significant unmet needs in the medical field, particularly in the areas of medical devices, biopharmaceuticals, and healthcare services.

RiverVest Venture Partners

RiverVest Venture Partners® is a leading venture capital firm building life science companies to address significant unmet needs of patients and deliver consistently strong returns to investors.

With headquarters in St. Louis and offices in San Diego and Cleveland, RiverVest accesses forward-thinking research and clinical expertise at leading institutions across the country to found and fund biopharma and medical device companies.

Entrepreneurs turn to RiverVest for the scientific, operational, financial, and investment expertise they need to achieve long-term success. RiverVest is committed to doing business the right way to deliver the best outcomes for patients, entrepreneurs and investors.

Established in 2000, RiverVest has funded more than 60 innovative life science companies and has assets under management of approximately $750 million.  For more information, please visit http://www.rivervest.com.

ZS Pharma

CardiaLen

Lumena Pharmaceuticals

Securus Medical Group

Smart Wires

Spruce Biosciences

Standard Bariatrics

Good Therapeutics

Otonomy

Mirum Pharmaceuticals

Accumetrics

Xilio Therapeutics, Inc.

Allakos

Amplyx Pharmaceuticals

Reneo Pharmaceuticals

RiverVest portfolio company Good Therapeutics, Inc. (now Bonum Therapeutics) is developing a new class of regulated protein therapeutics designed to deliver potent biological activity only where needed. These drugs could be a huge win for patients fighting cancer and other diseases. Roche acquired Good’s PD1-regulated IL-2 program in 2022 for $250 million plus potential milestone payments. We discuss that acquisition and more in RiverVest’s latest case study. Read it at rivervest.com or see a sample below.
 
In this case study, we recognize John Mulligan, Ph.D., Diane Hollenbaugh, John McKearn, the entire team at Bonum Therapeutics, and Roche.
 
Investor Syndicate: Codon Capital, Digitalis Ventures, RiverVest Venture Partners, Roche Venture Fund, and 503 Partners (formerly 3x5 Partners)
 
 #IL2 #PD1 #conditionallyactivetherapeutics #immunooncology #immunotherapy #biotech Neela Patel

At RiverVest, we find and fund innovation to address significant unmet medical needs and improve the lives of patients. During #WorldMitochondrialDiseaseWeek, we recognize the advocacy groups who support research into mitochondrial medicine that will one day lead to treatments and cures for #mito.
 
Read our recent article on the role of patient advocacy groups in drug development here: https://lnkd.in/gm6Sag7A
 
Reneo Pharmaceuticals Niall O'Donnell Wendy Newman Philip Yeske Alison Maguire Ashley H. Danielle Spangler MitoAction Mito Foundation Cure Mito Foundation The PolG Foundation and so many more! 

#MitoAwareness #mitochondrialdisease 

Patient advocacy groups are crucial to the development of drug therapeutics that are most impactful for the patient. For example, patient-derived data often include quality-of-life priorities that researchers don’t anticipate.

In RiverVest's latest "Expert Insight," we explore the role of patient advocacy groups in therapeutic drug development for patients with rare diseases. Learn how one #biopharma company is tackling mitochondrial disease by listening to the experts: the patients and families who live with the disease every day. 

Featured are United Mitochondrial Disease Foundation, Europe's The Lily Foundation, and Reneo Pharmaceuticals.

Niall O'Donnell  Philip Yeske Alison Maguire Wendy Newman Danielle Spangler Gregory J. Flesher Alejandro (Alex) Dorenbaum, M.D. Ashley H.

#raredisease #mito #mitochondrialdisease #PMM #LCFAOD #myopathy

RiverVest portfolio company Xilio Therapeutics, Inc. announced a collaboration with Roche to evaluate XTX101 anti-CTLA4 in combination with Roche’s atezolizumab in patients with microsatellite stable colorectal cancer. 

Metric
Company Name	RiverVest Venture Partners
Symbol
MSH ID	COM:RIVERVEST
Market	PRIVATE
Sector	Financial Services & Finance
Industry	Venture Capital & Private Equity
Country	US
Stage
Employee Count	18
Website	rivervest.com
LinkedIn	rivervest-venture-partners
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:RIVERVEST

RiverVest Venture Partners

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue